More legal trouble for KV Pharma; FDA sees uptick in Senate-approved funding;

> Investors have filed a class-action lawsuit against KV Pharma ($KV.A) for "false and/or misleading statements" the company made about the FDA granting it exclusive distribution rights for Makena, a drug for preventing premature births. Release

> The U.S. Senate yesterday approved funding of $2.5 billion for the FDA, up from $2.45 billion last year. It earmarked some of the funding for the recently passed Food Safety Modernization Act. Item

> Police have seized $30 million in counterfeit drugs in central China's Henan province. Story

> Contract manufacturer CMC Biologics will work with Daiichi Sankyo to develop and produce antibodies. Release

> Service provider Norwich Pharmaceuticals has boosted pilot production capabilities through a facility expansion that doubles its capacity. Announcement

> Lebanese security forces have shut down a counterfeit drug operation in Beirut, seizing 200 boxes of expired medicine and chemicals used in drug production. News

> High-potency API maker Carbogen Amcis has allied with liposomal formulations specialist Polymun Scientific. Story

> Service provider Norwich Pharmaceuticals has boosted pilot production capabilities through a facility expansion that doubles current capacity. Announcement

> High-potency API maker Carbogen Amcis has allied with liposomal formulations specialist Polymun Scientific. Story

> New on the FDA's drug shortages list: muscle-relaxant Pancuronium Bromide injection, 1 milligram/milliliter, 10-milliliter vial, due to a manufacturing delay at Hospira. Listing